| All Releases |
 |
Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017
May 23, 2013
|
19.2 KB
|
|
| |
NEW BRUNSWICK, N.J., May 23, 2013 /PRNewswire/ -- At a meeting today with industry analysts, senior leaders from the Janssen Pharmaceutical Companies of Johnson & Johnson (Janssen) announced they anticipate submitting more than 10 new product filings and more than 25 significant brand line extensions by 2017.
To view the multimedia assets as...
|
|
Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
May 21, 2013
|
15.3 KB
|
|
| |
ORLANDO, Fla. (May 21, 2013) -- Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from the global Phase 3 PROMISE study demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 79 percent of treatment-e...
|
|
Janssen Oncology Data to be Presented at 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Including ZYTIGA®, Ibrutinib and Daratumumab Data
May 20, 2013
|
60.6 KB
|
|
| |
RARITAN, NJ, May 15, 2013 - Janssen Research & Development, LLC (Janssen) announced that data related to three Janssen Oncology compounds have been selected for presentation at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 31-June 4, 2013 in Chicago, IL. Fourteen abstracts for ZYTIGA® (...
|
|
SIMPONI® (Golimumab) Receives FDA Approval For Ulcerative Colitis
May 15, 2013
|
20.8 KB
|
|
| |
Horsham, PA., May 15, 2013 -- Janssen Biotech, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI® (golimumab) for the treatment of moderately to severely active ulcerative colitis (UC) in adult patients who have demonstrated corticosteroid dependence or who have had an inadequate response to ...
|
|
Biosense Webster Reports Compelling Results from Ground-Breaking SMART-AF IDE Study on the Safety and Effectiveness of the THERMOCOOL® SMARTTOUCH™ Catheter
May 13, 2013
|
12.9 KB
|
|
| |
THERMOCOOL® SMARTTOUCH™ Catheter and Software
Module Enables Contact Force Sensing in the Ablation of Atrial
Fibrillation
DIAMOND BAR, Calif.--(BUSINESS WIRE)--
Biosense Webster, Inc., a worldwide leader in the diagnosis and
treatment of cardiac arrhythmia...
|
|
U.S. FDA Grants Priority Review to Simeprevir (TMC435) for Combination Treatment of Genotype 1 Chronic Hepatitis C
May 13, 2013
|
9.8 KB
|
|
| |
RARITAN, N.J., May 13, 2013 - Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application (NDA) for simeprevir (TMC435), an investigational NS3/4A protease inhibitor administered as a 150 mg capsule once daily with pegylated interferon ...
|
|
FDA Grants Premarket Approval (PMA) for the SEDASYS® System for Healthy Patients Undergoing Sedation During Routine Colonoscopy and EGD Procedures
May 3, 2013
|
9.6 KB
|
|
| |
Cincinnati, Ohio, May 3, 2013 - Sedasys, a Division of Ethicon Endo-Surgery, Inc. (Ethicon), today announced that the U.S. Food and Drug Administration (FDA) has granted PMA approval for the SEDASYS® System, the first computer-assisted personalized sedation (CAPS) system.
The SEDASYS System is indicated for the intravenous administra...
|
|
Janssen and Johnson & Johnson to Provide Webcast Presentation of Simeprevir Phase 3 Clinical Data Presented at The International Liver Congress of the European Association for the Study of the Liver (EASL)
May 2, 2013
|
6.1 KB
|
|
| |
NEW BRUNSWICK, N.J., May 2, 2013 /PRNewswire/ -- Janssen R&D Ireland (Janssen) and Johnson & Johnson (NYSE: JNJ) will provide a pre-recorded webcast for investors and other interested parties on Friday, May 3, at approximately 8:30 a.m., Eastern Time, to discuss simeprevir phase 3 clinical data presented at The International Liver Congress of the E...
|
|
Daratumumab Receives Breakthrough Therapy Designation in Double Refractory Multiple Myeloma from U.S. Food and Drug Administration
May 1, 2013
|
13.3 KB
|
|
| |
RARITAN, NJ - May 1, 2013 - Janssen Research & Development, LLC (Janssen) announced the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation for daratumumab for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy including a proteasome inhibitor (PI) and an ...
|
|
Ethicon Launches Next Generation Energy Device at American Society of Colon and Rectal Surgeons' Annual Meeting
Apr 26, 2013
|
10.8 KB
|
|
| |
PHOENIX (April 25, 2013) - To expand choice and help surgeons provide greater precision, Ethicon Endo-Surgery, Inc.(Ethicon) today announces the launch of the HARMONIC ACE®+ Shears with Adaptive Tissue Technology (HARMONIC ACE® + Shears), the next generation product in the best-in-class HARMONIC® portfolio of ultrasonic surgi...
|
|
INCIVO® Receives Positive Opinion From The Committee For Medicinal Products For Human Use (CHMP) For Twice Daily Dosing For Treatment Of Genotype-1 Hepatitis C Virus
Apr 26, 2013
|
119.6 KB
|
|
| |
Beerse, Belgium, 26 April, 2013 - Janssen Infectious Diseases-Diagnostics BVBA (Janssen), announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion recommending the approval of twice daily (BID) dosing of INCIVO® (telaprevir), a direct acting...
|
|
Johnson & Johnson Announces Dividend Increase of 8.2%
Apr 25, 2013
|
6.0 KB
|
|
| |
NEW BRUNSWICK, N.J., April 25, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that its Board of Directors has declared an 8.2% increase in the quarterly dividend rate, from $0.61 per share to $0.66 per share. The increase was announced this morning at the Annual Meeting of Shareholders in New Brunswick, NJ.
"In recogniti...
|
|
Janssen Submits Marketing Authorisation Application for Simeprevir (TMC435) to the European Medicines Agency for the Treatment of Adult Patients with Chronic Hepatitis C Genotype 1 or Genotype 4
Apr 24, 2013
|
11.8 KB
|
|
| |
Beerse, Belgium (April 24, 2013) - Janssen-Cilag International NV (Janssen) today announced it has submitted a Marketing Authorisation Application to the European Medicines Agency seeking approval for simeprevir (TMC435).
Simeprevir is a new generation NS3/4A protease inhibitor, administered as one capsule once daily with pegylated inter...
|
|
Johnson & Johnson to Host Pharmaceuticals Business Review
Apr 23, 2013
|
6.3 KB
|
|
| |
NEW BRUNSWICK, N.J., April 23, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will host a review of its Pharmaceuticals business for the Investment Community beginning at 8:30 a.m. (Eastern Time) on Thursday, May 23, 2013 at the Hyatt Regency Hotel in New Brunswick, New Jersey and ending at approximately 3:00 p.m.
Paul Stoffels, M.D., Wo...
|
|
Findings from Two Phase 3 Studies of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Patients
Apr 23, 2013
|
14.4 KB
|
|
| |
AMSTERDAM (April 23, 2013) -- Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from two global Phase 3 studies demonstrating that use of the investigational protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in 80 and 81 percent, respectively...
|
|
Johnson & Johnson Announces Sale of Elan American Depositary Shares to Elan
Apr 18, 2013
|
8.0 KB
|
|
| |
NEW BRUNSWICK, N.J., April 18, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced the sale to Elan Corporation, plc of approximately 82 million American Depositary Shares (ADS) of Elan held by Janssen Pharmaceutical (Janssen), an affiliate of Johnson & Johnson. This sale took place in accordance with the "Dutch Auction" tender offe...
|
|
Johnson & Johnson Reports 2013 First-Quarter Results:
Apr 16, 2013
|
48.5 KB
|
|
| |
NEW BRUNSWICK, N.J., April 16, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $17.5 billion for the first quarter of 2013, an increase of 8.5% as compared to the first quarter of 2012. Operational results increased 9.8% and the negative impact of currency was 1.3%. Domestic sales increased 11.2%. International sales...
|
|
Johnson & Johnson to Webcast Annual Meeting of Shareholders
Apr 11, 2013
|
6.7 KB
|
|
| |
NEW BRUNSWICK, N.J., April 11, 2013 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) will webcast its Annual Meeting of Shareholders at 10 a.m. (Eastern Time) on Thursday, April 25, 2013, from the Hyatt Regency Hotel in New Brunswick, N.J.
Investors and other interested parties may access the live webcast of the meeting by visiting the Company'...
|
|
Ibrutinib Receives Third Oncology Breakthrough Therapy Designation from U.S. Food and Drug Administration
Apr 8, 2013
|
15.9 KB
|
|
| |
RARITAN, N.J., April 8, 2013 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) announced today that the U.S. Food and Drug Administration (FDA) has granted a third Breakthrough Therapy Designation for the investigational oral Bruton's tyrosine kinase (BTK) inhibitor ibrutinib. Ibrutinib has been granted Breakthrough Therapy Designation ...
|
|
Next-Generation Circulating Tumor Cell Test Demonstrates High Efficiency and Accuracy in New Study
Apr 3, 2013
|
10.7 KB
|
|
| |
RARITAN, N.J., April 3, 2013 /PRNewswire/ -- Veridex, LLC (Veridex) announced today that the first study of the company's next-generation circulating tumor cell (CTC) technology, developed in collaboration with researchers at Massachusetts General Hospital (MGH), has been published in Science Translational Medicine. The collaboration, initially an...
|
